Home > Oncology > ASCO 2021 > ASCO 2021 Highlights Podcast

ASCO 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO 2021
  In this podcast, Medicom’s correspondent covers 6 presentations held at the American Society of Clinical Oncology (ASCO21), held 4-8 June 2021. The topics discussed are: Addition of 177Lu-PSMA-617 therapy to standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival, according to results from the randomised, phase 3 VISION trial. First results of the randomised, phase 3 CheckMate-648 study demonstrate superior overall survival of first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone for advanced or metastatic oesophageal squamous cell cancer. A first interim analysis of the OlympiA trial demonstrates significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant treatment with the PARP i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on